---
title: "Hanx Biopharmaceuticals Doses First Patient in Phase I Trial of OX40-Targeted ADC HX111"
description: "Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has initiated a Phase I clinical trial for HX111, an OX40-targeting antibody-drug conjugate aimed at treating relapsed or refractory lymphoma and solid tumors."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274815164.md"
published_at: "2026-02-04T12:49:34.000Z"
---

# Hanx Biopharmaceuticals Doses First Patient in Phase I Trial of OX40-Targeted ADC HX111

> Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has initiated a Phase I clinical trial for HX111, an OX40-targeting antibody-drug conjugate aimed at treating relapsed or refractory lymphoma and solid tumors. The first patient has been enrolled and dosed, marking HX111 as the first OX40-targeted ADC to enter clinical trials globally. No results are available yet as the study has just begun.

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. announced the initiation of a Phase I clinical trial for HX111, an OX40-targeting antibody-drug conjugate (ADC) developed for the treatment of relapsed or refractory lymphoma and solid tumors. The company has completed the first patient enrollment and dosing in this trial. HX111 is the first OX40-targeted ADC globally to publicly enter the clinical stage. According to the announcement, there are currently no results presented, as the study has recently begun. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals (Wuhan) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260204-12014780), on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [03378.HK - HANXBIO-B](https://longbridge.com/en/quote/03378.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hanx Biopharmaceuticals Sets Out Board and Committee Structure | Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has announced its board composition, led by chairman Dr. Zhang Faming, includin | [Link](https://longbridge.com/en/news/275228301.md) |
| Hanx Biopharmaceuticals Files Director List with HKEX | Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has submitted an updated director list to the Hong Kong Stock Exchange. The Boa | [Link](https://longbridge.com/en/news/275224008.md) |
| A Look At Agree Realty (ADC) Valuation After Raised 2026 Investment Guidance And Dividend Increase | Agree Realty (ADC) has raised its 2026 investment guidance and increased its annual dividend, leading to a positive mark | [Link](https://longbridge.com/en/news/276090924.md) |
| Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | [Link](https://longbridge.com/en/news/276393466.md) |
| UK MHRA approves CStone’s sugemalimab for unresectable stage III NSCLC | CStone Pharmaceuticals announced that the UK MHRA has approved sugemalimab as a monotherapy for adults with unresectable | [Link](https://longbridge.com/en/news/276548236.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.